Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported new data from its Phase III trial, Startverso, which evaluated faldaprevir in combination with pegylated interferon and ribavirin (PegIFN/RBV) in patients with genotype-1 hepatitis C (HCV) who have not received previous treatment treatment-experienced patients, and HIV co-infected patients.